John Kenneth Morrow
Impact in
-
- Ubiquitin and proteasome pathways
- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
- Protein Structure and Dynamics
- Oncology top 10%
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
Papers in
-
- Ubiquitin and proteasome pathways 4
- Protein Degradation and Inhibitors 2
- Histone Deacetylase Inhibitors Research 2
- 14-3-3 protein interactions 2
- Protein Structure and Dynamics 2
- PI3K/AKT/mTOR signaling in cancer 2
-
- Computational Drug Discovery Methods 6
- Co-authors
- Shuxing Zhang (11 shared papers)Hui‐Kuan Lin (2 shared papers)Guoxiang Jin (2 shared papers)Chien‐Feng Li (2 shared papers)Dazhi Xu (2 shared papers)Mien‐Chie Hung (1 shared paper)Chia‐Hsin Chan (1 shared paper)Loren Stagg (1 shared paper)
- Journals
- Current Drug Metabolism (2 papers)Current Pharmaceutical Design (2 papers)Journal of Pharmacology and Experimental Therapeutics (1 paper)Molecular Pharmaceutics (1 paper)Recent Patents on Anti-Cancer Drug Discovery (1 paper)
- Partner nations
- United StatesNetherlandsTaiwan
In The Last Decade
John Kenneth Morrow
13 papers receiving 822 citations
Peers
Comparison fields: 5 of 89
- Molecular Biology 680
- Oncology 238
- Cancer Research 90
- Computational Theory and Mathematics 92
- Pharmacology 43
Countries citing papers authored by John Kenneth Morrow
This map shows the geographic impact of John Kenneth Morrow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Kenneth Morrow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Kenneth Morrow more than expected).
Fields of papers citing papers by John Kenneth Morrow
This network shows the impact of papers produced by John Kenneth Morrow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Kenneth Morrow. The network helps show where John Kenneth Morrow may publish in the future.
Co-authors
The 25 scholars most cited alongside John Kenneth Morrow, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 318 | |
| 2 | 2018 | 139 | |
| 3 | 2015 | 87 | |
| 4 | 2012 | 76 | |
| 5 | 2012 | 57 | |
| 6 | 2010 | 36 | |
| 7 | 2010 | 34 | |
| 8 | 2010 | 31 | |
| 9 | 2012 | 29 | |
| 10 | 2023 | 16 | |
| 11 | 2012 | 8 | |
| 12 | 2012 | 5 | |
| 13 | 2023 | 1 |
About John Kenneth Morrow
John Kenneth Morrow is a scholar working on Molecular Biology, Computational Theory and Mathematics, Pharmacology, Organic Chemistry and Pathology and Forensic Medicine, having authored 13 papers that have together received 837 indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (6 papers), Ubiquitin and proteasome pathways (4 papers), Protein Degradation and Inhibitors (2 papers), Histone Deacetylase Inhibitors Research (2 papers), Microbial Natural Products and Biosynthesis (2 papers), 14-3-3 protein interactions (2 papers), Protein Structure and Dynamics (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). The work is most often cited by research in Molecular Biology (680 citations), Oncology (238 citations), Cancer Research (90 citations), Computational Theory and Mathematics (92 citations) and Pharmacology (43 citations). John Kenneth Morrow has collaborated with scholars based in United States, Netherlands and Taiwan. Frequent co-authors include Shuxing Zhang, Hui‐Kuan Lin, Guoxiang Jin, Chien‐Feng Li, Dazhi Xu, Mien‐Chie Hung, Chia‐Hsin Chan, Loren Stagg, Christopher J. Logothetis and Yuan Gao. Their work appears in journals such as Current Drug Metabolism, Current Pharmaceutical Design, Journal of Pharmacology and Experimental Therapeutics, Molecular Pharmaceutics and Recent Patents on Anti-Cancer Drug Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.